Abstract
This analytical, observational, retrospective, case-control study was designed to describe clinical presentation, biochemical disease severity, presence, and severity of metabolic and cardiovascular complications in patients diagnosed as having acromegaly at 60 yr or older (no.=57) as compared to sex- and age-matched healthy controls. Patients and controls underwent a complete endocrine, metabolic, and cardiovascular check-up. The age at diagnosis was equally distributed between 60 to 75 yr while only a minority of the patients (5.3%) was diagnosed after 75 yr. Median GH and IGF-I levels were 15 μg/l and 557 μg/l. The prevalence of microadenomas, enclosed macroadenomas, and extrasellar/invasive macroadenomas was 30%, 49%, and 21%, respectively. All patients had joint complaints and goiter (euthyroid in 65% and pre-toxic/toxic in 35%), 82% had hypertension, 58% diabetes and 54% had both. As compared to controls, a higher number of patients were receiving treatment with anti-arrhythmiacs (p=0.033), anti-aggregants (p=0.013), levothyroxine (p=0.015), and metformin (p=0.022). Nevertheless, the patients had higher systolic and diastolic blood pressure, heart rate, left ventricular mass index, lipids, glucose and insulin levels as well as percent function of β cells than controls. In conclusion, the high prevalence of systemic complications makes elderly acromegalics more susceptible than controls to cardiovascular events. We suggest that an accurate clinical check-up and, possibly, a more aggressive treatment of hypertension and diabetes are required in elderly acromegalics.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Colao A, Lombardi G. Growth-hormone and prolactin excess. Lancet 1998, 352: 1455–61.
Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999, 2: 29–41.
Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf) 1980, 12: 71–9.
Bengtsson B, Eden S, Ernest I, Oden A, Sjogren B. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 1988, 223: 327–35.
Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. The United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998, 83: 2730–4.
Swearingen B, Barker FG 2nd, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998, 83: 3419–26.
Beauregard C, Truong U, Hardy J, Serri O. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 2003, 58: 86–91.
Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004, 89: 667–74.
Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS. Growth Hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004, 89: 1613–7.
Kauppinen-Makelin R, Sane T, Reunanen A, et al. A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 2005, 90: 4081–6.
Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004, 25: 102–52.
Minniti G, Esposito V, Piccirilli M, Fratticci A, Santoro A, Jaffrain-Rea ML. Diagnosis and management of pituitary tumours in the elderly: a review based on personal experience and evidence of literature. Eur J Endocrinol 2005, 153: 723–35.
Colao A, Spiezia S, Di Somma C, et al. Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age. J Endocrinol Invest 2005, 28: 440–8.
Castelli WP. Lipid, risk factors and ischaemic heart disease. Atherosclerosis 1996, 124 (Suppl): S1–9.
Grundy SM, Cleeman JI, Bairey Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004, 110: 227–39.
American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2006, 29: S43–8.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28: 412–9.
Vitale G, Pivonello R, Auriemma RS, et al. Hypertension in acromegaly and in the normal population: prevalence and determinants. Clin Endocrinol (Oxf) 2005, 63: 470–6.
The seventh report of the joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. JAMA 2003, 289: 2560–1
Colao A, Marzullo P, Ferone D, et al. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J Clin Endocrinol Metab 2000, 85: 3132–40.
Colao A, Spinelli L, Cuocolo A, et al. Cardiovascular consequences of early-onset growth hormone excess. J Clin Endocrinol Metab 2002, 87: 3097–104.
Colao A, Marzullo P, Cuocolo A, et al. Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clin Endocrinol (Oxf) 2003, 58: 169–76.
Sahn DJ, De Maria A, Kissio J, Weyman A. The committee on M-mode standardization of the American Society of Echocardiography. Recommendations regarding quantification in M-mode echocardiography: results of a survey of echocardiography measurements. Circulation 1978, 58: 1072–83.
Devereux RB. Detection of left ventricular hypertrophy by M-mode echocardiography. Anatomic validation, standardization and comparison to the other methods. Hypertension 1987, 9(Suppl 2): 19–26.
Colao A, Ferone D, Marzullo P, et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001, 86: 2779–86.
Colao A, Pivonello R, Cappabianca P, et al. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly. Clin Endocrinol (Oxf) 2005, 63: 342–9.
Cohen DL, Bevan JS, Adams CBT. The presentation and management of pituitary tumours in the elderly. Age Ageing 1989, 18: 247–52.
Turner HE, Adams CB, Wass JA. Pituitary tumors in the elderly: a 20 year experience. Eur J Endocrinol 1999, 140: 383–9.
Benbow SJ, Foy P, Jones B, Shaw D, MacFarlane IA. Pituitary tumours presenting in the elderly: management and outcome. Clin Endocrinol (Oxf) 1997, 46: 657–60.
Kovacs K, Ryan N, Horvath E, Singer W, Ezrin C. Pituitary adenomas in old age. J Gerontol 1980, 35: 16–22.
Puchner MJ, Knappe UJ, Ludecke DK. Pituitary surgery in elderly patients with acromegaly. Neurosurgery 1995, 36: 677–84.
Minniti G, Jaffrain-Rea ML, Esposito V, et al. Surgical treatment and clinical outcome of GH-secreting adenomas in elderly patients. Acta Neurochir (Wien) 2001, 143: 1205–11.
Gasperi M, Martino E, Manetti L, et al. Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-centerstudy. J Endocrinol Invest 2002, 25: 240–5.
Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Stud of Aging. J Clin Endocrinol Metab 2001, 86: 724–31.
Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002, 87: 589–98.
Desailloud R, Crépin-Hemon S, Simovic-Corroyer B. Acromegaly in elderly people. Ann Endocrinol (Paris) 2005, 66: 540–4.
van der Lely AJ, Harris AG, Lamberts SW. The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex. Clin Endocrinol (Oxf) 1992, 37: 181–5.
Colao A, Amato G, Pedroncelli AM, et al. Gender- and agerelated difference in the endocrine parameters of acromegaly. J Endocrinol Invest 2002, 25: 532–8.
Colao A, Pivonello R, Auriemma RS, et al. Predictors of tumor shrinkage after primary therapy with somatostatin analogues in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab 2006, 91: 2112–8.
Parkinson C, Ryder WD, Trainer PJ, Sensus Acromegaly Study Group. The relationship between serum GH and serum IGF-I in acromegaly is gender-specific. J Clin Endocrinol Metab 2001, 86: 5240–4.
Edén Engström B, Burman P, Karlsson FA. Men with acromegaly need higher doses of octreotide than women. Clin Endocrinol (Oxf) 2002, 56: 73–7.
Bayes-Genis A, Conover CA, Schwartz RS. The Insulin-Like Growth Factor Axis. A review of atherosclerosis and restenosis. Circ Res 2000, 86: 125–30.
Luft R, Cerasi E, Hamberger CA. Studies on the pathogenesis of diabetes in acromegaly. Acta Endocrinol (Copenh) 1967, 56: 593–607.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Colao, A., Pivonello, R., Spinelli, L. et al. A retrospective analysis on biochemical parameters, cardiovascular risk and cardiomyopathy in elderly acromegalic patients. J Endocrinol Invest 30, 497–506 (2007). https://doi.org/10.1007/BF03346334
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03346334